Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461952 · ClinicalTrials.gov registry record · Phase 2
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
A Phase 2 study, sponsored by Canadian Cancer Trials Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03461952: Clinical Trial Phase 2 study, sponsored by Canadian Cancer Trials Group.
NCT03461952 is a Phase 2 study that was terminated before completion, run by Canadian Cancer Trials Group. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03461952, a Phase 2 study, was terminated before completion, sponsored by Canadian Cancer Trials Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.
Primary Outcome
Objective Response Rate by RECIST 1.1: CR, PR, SD, or PD
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-02-09 |
| Phase | Phase 2 |
Why NCT03461952 stopped before completion
NCT03461952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03461952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03461952 about?
NCT03461952 is a clinical study titled "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)". The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab h...
What is the current status of trial NCT03461952?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-03-11. Estimated completion is 2022-02-09.
What interventions are being tested in trial NCT03461952?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03461952?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03461952's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI